The FDA approved Eli Lilly’s baricitinib drug to regrow hair in patients with alopecia; the American Medical Association (AMA) adopts resolutions that go against criminalization of abortion; an experimental amyotrophic lateral sclerosis (ALS) therapy under review with the FDA has been approved in Canada.
The researchers underscored the importance of the patient voice in the field, as some aspects of treatment can only be assessed through the patient.
The researchers highlighted that the dermatology field is considered one of the least diverse and most competitive specialties.
A recent study found that patient assessments of symptoms are fit for purpose and can be used by adolescents with alopecia areata in clinical trials and practice.
Chargemaster lists may encourage patients to shop around for services, but the authors of this report said the implications of this change for dermatology are not well-defined.
The findings come from a novel longitudinal analysis of 400 patients, which the researchers said validates and further underscores the utility of laboratory parameters for the management of hidradenitis suppurativa.
Hidradenitis suppurativa (HS) was associated with a variety of comorbid conditions, from psoriasis to hypertension.
According to the researchers of this new study, the biomarker may have potential for use with clinical scores in treatment decisions or in clinical trials that focus on hidradenitis suppurativa (HS).
Hilary Baldwin, MD, medical director, Acne Treatment and Research Center, discusses new therapies for acne and unmet needs for the condition.
Within 4 weeks of starting treatment, patients experienced improvements in their condition, indicating an anti-inflammatory effect of the treatment.
Hilary Baldwin, MD, medical director, Acne Treatment and Research Center, explains the microencapsulation technology in Twyneo cream and what research went into its development.
A retrospective analysis found that patients with hidradenitis suppurativa had a high burden of disease despite active treatment by a dermatologist.
Interviewing both patients and providers, researchers found that while having effective treatments for hidradenitis suppurativa (HS) took precedence across the board, some priorities varied among the 2 groups.
The researchers warned that while the data revealed into rosacea subtypes, their findings should be interpreted with caution due to a high degree of heterogeneity.
When including patients who had a mole check or cancer screening, the proportion of patients with at least 1 dermatological condition or disease increased to 47%; both non-melanoma and melanoma skin cancers were among the top 12 skin diseases reported in the study.
As potential new treatment options emerge for hidradenitis suppurativa (HS), an inflammatory condition, researchers emphasized the importance of clinicians being prepared to manage patients that have additional health factors.
A new study has found that internalized skin bias has a role in diminishing HRQOL and negatively affects mental health among these patients.
The findings come from over 60,000 records from the National Ambulatory Medical Care Survey, which accounted for nearly 1.5 billion dermatology visits in the United States.
If corroborated by longer-term studies, researchers argued the treatment could be a safe short-term treatment for patients.
Public financial statements from 9 dermatology groups backed by private equity (PE) were analyzed by the researchers, who described a significant decrease in debt valuations of these groups both before and during the COVID-19 pandemic.
Among patients with atopic dermatitis, the risk and severity of acne varied based on age and sex.
In this new analysis, results showed that CCL3, CXCL8, CXCL9, and CXCL10 may be indicators of disease severity.
The cause of the increase is 2-fold: an increased push for personal hygiene practices and the use of personal protective equipment for health care workers.
Data from 22 studies were collected on reported hair loss with isotretinoin treatment, showing a hair loss frequency of 3.2% for patients receiving <0.5 mg/kg/day and a frequency of 5.7% for patients receiving ≥0.5 mg/kg/day.
Steven Feldman, MD, PhD, professor of dermatology at Wake Forest School of Medicine, discusses what makes clascoterone (Winlevi) different from past acne treatments.
